fda semaglutide warning news october 2025 National Hispanic Medical Association | After compounded GLP-1 drugs were banned, counterfeit versions continued to circulate — and still do today. Understanding the risks and FDA Decisions Expected: October 2025
Description
Parexel review of obesity trials planned, ongoing, or completed as of 2025 (unpublished data)
Just beyond
This medication works by mimicking a natural hormone in your body called GLP-1, which regulates appetite and blood sugar
doi: 10.1016/j.intimp.2020.106715
The Hims & Hers release comes amid a shortage of GLP-1s, as the demand for medications to treat obesity and diabetes outpaces the supply
With physician supervised semaglutide treatment in New Hampshire, patients receive personalized care
